BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ison MG. Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza Other Respir Viruses 2013;7 Suppl 1:7-13. [PMID: 23279892 DOI: 10.1111/irv.12046] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Massari S, Nannetti G, Desantis J, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, Palù G, Cruciani G, Loregian A, Goracci L, Tabarrini O. A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein–Basic Protein 1 (PA-PB1) Subunits. J Med Chem 2015;58:3830-42. [DOI: 10.1021/acs.jmedchem.5b00012] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 8.1] [Reference Citation Analysis]
2 Zyryanov SK, Butranova OI, Gaidai DS, Kryshen KL. [Pharmacotherapy for acute respiratory infections caused by influenza viruses: current possibilities]. Ter Arkh 2021;93:114-24. [PMID: 33720636 DOI: 10.26442/00403660.2021.01.200551] [Reference Citation Analysis]
3 Tsuruoka Y, Nakajima T, Kanda M, Hayashi H, Matsushima Y, Yoshikawa S, Nagata M, Koike H, Nagano C, Sekimura K, Hashimoto T, Takano I, Shindo T. Simultaneous determination of amantadine, rimantadine, and memantine in processed products, chicken tissues, and eggs by liquid chromatography with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2017;1044-1045:142-8. [PMID: 28107701 DOI: 10.1016/j.jchromb.2017.01.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
4 Wu X, Wu X, Sun Q, Zhang C, Yang S, Li L, Jia Z. Progress of small molecular inhibitors in the development of anti-influenza virus agents. Theranostics 2017;7:826-45. [PMID: 28382157 DOI: 10.7150/thno.17071] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
5 Zhang J, Hu Y, Musharrafieh R, Yin H, Wang J. Focusing on the Influenza Virus Polymerase Complex: Recent Progress in Drug Discovery and Assay Development. Curr Med Chem 2019;26:2243-63. [PMID: 29984646 DOI: 10.2174/0929867325666180706112940] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
6 Arns S, Balgi AD, Shimizu Y, Pfeifer TA, Kumar N, Shidmoossavee FS, Sun S, Tai SS, Agafitei O, Jaquith JB, Bourque E, Niikura M, Roberge M. Novel spirothiazamenthane inhibitors of the influenza A M2 proton channel. Eur J Med Chem 2016;120:64-73. [PMID: 27187859 DOI: 10.1016/j.ejmech.2016.05.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
7 Ison MG. Optimizing antiviral therapy for influenza: understanding the evidence. Expert Rev Anti Infect Ther 2015;13:417-25. [PMID: 25695406 DOI: 10.1586/14787210.2015.1018183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
8 Shtro AA, Zarubaev VV, Luzina OA, Sokolov DN, Salakhutdinov NF. Derivatives of usnic acid inhibit broad range of influenza viruses and protect mice from lethal influenza infection. Antivir Chem Chemother 2015;24:92-8. [PMID: 27022094 DOI: 10.1177/2040206616636992] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
9 Mallajosyula VV, Citron M, Ferrara F, Temperton NJ, Liang X, Flynn JA, Varadarajan R. Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 Subtype. Front Immunol 2015;6:329. [PMID: 26167164 DOI: 10.3389/fimmu.2015.00329] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
10 Spanakis N, Pitiriga V, Gennimata V, Tsakris A. A review of neuraminidase inhibitor susceptibility in influenza strains. Expert Rev Anti Infect Ther 2014;12:1325-36. [PMID: 25301229 DOI: 10.1586/14787210.2014.966083] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
11 He JY, Li C, Wu G. Discovery of potential drugs for human-infecting H7N9 virus containing R294K mutation. Drug Des Devel Ther 2014;8:2377-90. [PMID: 25489236 DOI: 10.2147/DDDT.S74061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
12 Vardanyan R, Hruby V. Antiviral Drugs. Synthesis of Best-Seller Drugs. Elsevier; 2016. pp. 687-736. [DOI: 10.1016/b978-0-12-411492-0.00034-1] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
13 Zarubaev VV, Pushkina EA, Borisevich SS, Galochkina AV, Garshinina AV, Shtro AA, Egorova AA, Sokolova AS, Khursan SL, Yarovaya OI, Salakhutdinov NF. Selection of influenza virus resistant to the novel camphor-based antiviral camphecene results in loss of pathogenicity. Virology 2018;524:69-77. [DOI: 10.1016/j.virol.2018.08.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
14 Cantwell L, Perkins J. Infectious Disease Emergencies in Oncology Patients. Emerg Med Clin North Am 2018;36:795-810. [PMID: 30297005 DOI: 10.1016/j.emc.2018.06.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
15 Kim JE, Kim UJ, Kim HK, Cho SK, An JH, Kang SJ, Park KH, Jung SI, Jang HC. Predictors of viral pneumonia in patients with community-acquired pneumonia. PLoS One 2014;9:e114710. [PMID: 25531901 DOI: 10.1371/journal.pone.0114710] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
16 Sanchez JL, Cooper MJ, Myers CA, Cummings JF, Vest KG, Russell KL, Sanchez JL, Hiser MJ, Gaydos CA. Respiratory Infections in the U.S. Military: Recent Experience and Control. Clin Microbiol Rev 2015;28:743-800. [PMID: 26085551 DOI: 10.1128/CMR.00039-14] [Cited by in Crossref: 44] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
17 Hodinka RL. Respiratory RNA Viruses. Microbiol Spectr 2016;4. [PMID: 27726802 DOI: 10.1128/microbiolspec.DMIH2-0028-2016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
18 Galochkina AV, Bollikanda RK, Zarubaev VV, Tentler DG, Lavrenteva IN, Slita AV, Chirra N, Kantevari S. Synthesis of novel derivatives of 7,8-dihydro-6H-imidazo[2,1-b][1,3]benzothiazol-5-one and their virus-inhibiting activity against influenza A virus. Arch Pharm (Weinheim) 2019;352:e1800225. [PMID: 30520524 DOI: 10.1002/ardp.201800225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
19 Liu Q, Liu DY, Yang ZQ. Characteristics of human infection with avian influenza viruses and development of new antiviral agents. Acta Pharmacol Sin 2013;34:1257-69. [PMID: 24096642 DOI: 10.1038/aps.2013.121] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
20 Stockdale TP, Williams CM. Pharmaceuticals that contain polycyclic hydrocarbon scaffolds. Chem Soc Rev 2015;44:7737-63. [DOI: 10.1039/c4cs00477a] [Cited by in Crossref: 109] [Cited by in F6Publishing: 12] [Article Influence: 15.6] [Reference Citation Analysis]
21 Brison E, Jacomy H, Desforges M, Talbot PJ. Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus. J Virol 2014;88:1548-63. [PMID: 24227863 DOI: 10.1128/JVI.02972-13] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
22 Jang Y, Lee HW, Shin JS, Go YY, Kim C, Shin D, Malpani Y, Han SB, Jung Y, Kim M. Antiviral activity of KR-23502 targeting nuclear export of influenza B virus ribonucleoproteins. Antiviral Research 2016;134:77-88. [DOI: 10.1016/j.antiviral.2016.07.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
23 Wu Y, Bi Y, Vavricka CJ, Sun X, Zhang Y, Gao F, Zhao M, Xiao H, Qin C, He J, Liu W, Yan J, Qi J, Gao GF. Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. Cell Res 2013;23:1347-55. [PMID: 24165891 DOI: 10.1038/cr.2013.144] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 8.0] [Reference Citation Analysis]
24 Neagu IA, Olejarz J, Freeman M, Rosenbloom DIS, Nowak MA, Hill AL. Life cycle synchronization is a viral drug resistance mechanism. PLoS Comput Biol 2018;14:e1005947. [PMID: 29447150 DOI: 10.1371/journal.pcbi.1005947] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
25 Qiu S, Shen Y, Pan H, Wang J, Zhang Q. Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. Infectious Diseases 2015;47:808-19. [DOI: 10.3109/23744235.2015.1067369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
26 Alves Galvão MG, Rocha Crispino Santos MA, Alves da Cunha AJ. Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst Rev 2014;:CD002745. [PMID: 25415374 DOI: 10.1002/14651858.CD002745.pub4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
27 Bassetti M, Castaldo N, Carnelutti A. Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives. Expert Opin Pharmacother 2019;20:1711-8. [PMID: 31169040 DOI: 10.1080/14656566.2019.1626824] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
28 Parra-Rojas C, Nguyen VK, Hernandez-Mejia G, Hernandez-Vargas EA. Neuraminidase Inhibitors in Influenza Treatment and Prevention⁻Is It Time to Call It a Day? Viruses 2018;10:E454. [PMID: 30149615 DOI: 10.3390/v10090454] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
29 Kimberlin DW. Antiviral Agents. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2018. pp. 1551-1567.e6. [DOI: 10.1016/b978-0-323-40181-4.00295-4] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 De Clercq E. Dancing with chemical formulae of antivirals: A panoramic view (Part 2). Biochemical Pharmacology 2013;86:1397-410. [DOI: 10.1016/j.bcp.2013.09.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
31 Ison MG. Optimum timing of oseltamivir: lessons from Bangladesh. Lancet Infect Dis 2014;14:88-9. [PMID: 24268592 DOI: 10.1016/S1473-3099(13)70287-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
32 Lampejo T. Influenza and antiviral resistance: an overview. Eur J Clin Microbiol Infect Dis 2020;39:1201-8. [PMID: 32056049 DOI: 10.1007/s10096-020-03840-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 21.5] [Reference Citation Analysis]
33 Ustinov NB, Zavyalova EG, Smirnova IG, Kopylov AM. The Power and Limitations of Influenza Virus Hemagglutinin Assays. Biochemistry (Mosc) 2017;82:1234-48. [PMID: 29223151 DOI: 10.1134/S0006297917110025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
34 Skarlupka AL, Bebin-Blackwell AG, Sumner SF, Ross TM. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains. J Virol 2021;95:e0075921. [PMID: 34160258 DOI: 10.1128/JVI.00759-21] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
35 Zeng MS, Yu WD, Wang HX, Xu PP, Liu JY. Puerarin reduces impairment of intestinal and adipose immune responses to influenza virus infection in mice. Arch Virol 2021;166:2387-97. [PMID: 34114139 DOI: 10.1007/s00705-021-05112-z] [Reference Citation Analysis]
36 Bougarn S, Boughorbel S, Chaussabel D, Marr N. A curated transcriptome dataset collection to investigate the blood transcriptional response to viral respiratory tract infection and vaccination. F1000Res 2019;8:284. [PMID: 31231515 DOI: 10.12688/f1000research.18533.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
37 Sokolova AS, Yarovaya OC, Korchagina DV, Zarubaev VV, Tretiak TS, Anfimov PM, Kiselev OI, Salakhutdinov NF. Camphor-based symmetric diimines as inhibitors of influenza virus reproduction. Bioorg Med Chem 2014;22:2141-8. [PMID: 24631360 DOI: 10.1016/j.bmc.2014.02.038] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
38 Kamali A, Holodniy M. Influenza treatment and prophylaxis with neuraminidase inhibitors: a review. Infect Drug Resist 2013;6:187-98. [PMID: 24277988 DOI: 10.2147/IDR.S36601] [Cited by in Crossref: 18] [Cited by in F6Publishing: 35] [Article Influence: 2.0] [Reference Citation Analysis]
39 Leung SSY, Parumasivam T, Tang P, Chan HK. A Proof-of-Principle Setup for Delivery of Relenza® (Zanamivir) Inhalation Powder to Intubated Patients. J Aerosol Med Pulm Drug Deliv 2016;29:30-5. [PMID: 25974393 DOI: 10.1089/jamp.2014.1179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
40 Margine I, Krammer F. Animal models for influenza viruses: implications for universal vaccine development. Pathogens 2014;3:845-74. [PMID: 25436508 DOI: 10.3390/pathogens3040845] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 8.8] [Reference Citation Analysis]
41 El-alfy NZI, Sakr SM, Mahmoud MF, Omar HA. Effects of Tamiflu and Adamine on histology and ultrastructure of the liver of albino mice. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00112-9] [Reference Citation Analysis]
42 Shtro AA, Zarubaev VV, Luzina OA, Sokolov DN, Kiselev OI, Salakhutdinov NF. Novel derivatives of usnic acid effectively inhibiting reproduction of influenza A virus. Bioorg Med Chem 2014;22:6826-36. [PMID: 25464881 DOI: 10.1016/j.bmc.2014.10.033] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
43 Laure M, Hamza H, Koch-Heier J, Quernheim M, Müller C, Schreiber A, Müller G, Pleschka S, Ludwig S, Planz O. Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model. Antiviral Res 2020;178:104806. [PMID: 32304723 DOI: 10.1016/j.antiviral.2020.104806] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]